Osivax
- Address
- 70 Rue Saint Jean De Dieu
Sponsor Overview
Specializations
Influenza Vaccination
Clinical research in influenza centers on preventive vaccines designed to reduce type A influenza illness in healthy adults. The sponsor’s studies focus on immunogenicity, efficacy, and safety in the context of seasonal respiratory infection.
- Influenza vaccine development
- Type A influenza prevention
- Respiratory viral disease protection
The work reflects interest in adult vaccination strategies and immune protection against laboratory-confirmed influenza illness.
Sarbecovirus Vaccines
Research activity also includes sarbecovirus vaccine development, with attention to candidate vaccines intended to support protection against coronavirus threats. The clinical focus includes safety, reactogenicity, and immune response assessment in adults.
- Sarbecovirus candidate vaccines
- Coronavirus immunisation
- Adult vaccine safety
These studies place emphasis on intramuscular vaccination and the evaluation of immune activity relevant to broad coronavirus coverage.
Cell-mediated Immunity and Immunogenicity
The sponsor’s trial portfolio includes detailed assessment of cell-mediated immune responses, with measurement of antigen-specific T-cell activity and broader immunogenicity outcomes after vaccination. These endpoints are central to understanding vaccine-induced protection in adult participants.
- T-cell response evaluation
- Antigen-specific immune responses
- Vaccine immunogenicity
Such work supports the clinical development of vaccines aimed at generating measurable adaptive immune responses.
Preventive Infectious Disease Research
Across its active studies, the sponsor is engaged in preventive infectious disease research in healthy adults, with a therapeutic interest in respiratory pathogens and vaccine-based disease prevention. The portfolio spans both influenza and coronavirus targets.
- Adult preventive vaccination
- Respiratory infection prevention
- Healthy volunteer studies
Clinical activity is concentrated on vaccine candidates intended for infectious disease prevention rather than treatment.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy, Immunogenicity, and Safety of OVX836 Influenza Vaccine in Preventing RT-PCR-Confirmed Influenza Type A in Healthy Adults Aged 18-59: A Phase 2b Study |  Belgium Finland France Germany | Not Recruiting |
| Evaluation of Safety and Immunogenicity of OVX033 Sarbecovirus Vaccine in Adults: A Phase 1/2a Randomized, Double-Blind, Multicenter Study | France | Not Yet Recruiting |
| Phase 1 Study on Safety and Immunogenicity of OVX033 Vaccine in Sarbecovirus Diseases in Healthy Adults Aged 18-49 | France | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 11 sites across their trial portfolio.
Therapeutic Focus
- 1.Virus Diseases3 trials182 other sponsors
Partnered Research Centres
11 centres- Address
- 27 Rue du Faubourg Saint-Jacques, 75014 Paris
- Address
- 165, Chemin du Grand Revoyet, Pavillon Médical Bat 1A, Pierre-Bénite, Rhône, 69494 Pierre Benite
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- 16 Boulevard De Bulgarie, Bp 90349, 35200 Rennes
- Address
- Kluuvikatu 7 Floor 5, 00100 Helsinki
- Address
- Nationalestraat 155, 2000 Antwerp
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Osivax.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.